MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Tsao, 2005, Erlotinib in lung cancer molecular and clinical predictors of outcome, N Engl J Med, 353, 133, 10.1056/NEJMoa050736 Hirsch, 2006, Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer, J Clin Oncol, 24, 5034, 10.1200/JCO.2006.06.3958 Cappuzzo, 2005, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer, J Natl Cancer Inst, 97, 643, 10.1093/jnci/dji112 Cappuzzo, 2007, Prospective study of gefitinib in EGFR FISH positive/P-Akt positive or never smoker patients with advanced non-small cell lung cancer (NSCLC): the ONCOBELL trial, J Clin Oncol, 25, 2248, 10.1200/JCO.2006.09.4300 She, 2003, Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling, Clin Cancer Res, 9, 4340 Bianco, 2003, Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors, Oncogene, 22, 2812, 10.1038/sj.onc.1206388 Chakravarti, 2002, Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling, Cancer Res, 62, 200 Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med, 2, e17, 10.1371/journal.pmed.0020017 Massarelli, 2007, Kras mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer, Clin Cancer Res, 13, 2890, 10.1158/1078-0432.CCR-06-3043 Shigematsu, 2005, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers, J Natl Cancer Inst, 97, 339, 10.1093/jnci/dji055 Kobayashi, 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N Engl J Med, 352, 786, 10.1056/NEJMoa044238 Balak, 2006, Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors, Clin Cancer Res, 12, 6494, 10.1158/1078-0432.CCR-06-1570 Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478 Bean, 2007, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib, Proc Natl Acad Sci USA, 104, 20932, 10.1073/pnas.0710370104 Ma, 2003, c-Met: structure, functions and potential for therapeutic inhibition, Cancer Metastasis Rev, 22, 309, 10.1023/A:1023768811842 Christensen, 2005, c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention, Cancer Lett, 225, 1, 10.1016/j.canlet.2004.09.044 Ichimura, 1996, Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance, Jpn J Cancer Res, 87, 1063, 10.1111/j.1349-7006.1996.tb03111.x Tsao, 1998, Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers, Lung Cancer, 20, 1, 10.1016/S0169-5002(98)00007-5 Masuya, 2004, The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients, Br J Cancer, 90, 1555, 10.1038/sj.bjc.6601718 Kong-Beltran, 2006, Somatic mutations lead to an oncogenic deletion of met in lung cancer, Cancer Res, 66, 283, 10.1158/0008-5472.CAN-05-2749 Kuniyasu, 1992, Frequent amplification of the c-met gene in scirrhous type stomach cancer, Biochem Biophys Res Commun, 189, 227, 10.1016/0006-291X(92)91548-5 Tsujimoto, 1997, Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer, Virchows Arch, 431, 383, 10.1007/s004280050115 Hara, 1998, Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization, Lab Invest, 78, 1143 Miller, 2006, Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma, Oncogene, 25, 409, 10.1038/sj.onc.1209057 Zhao, 2005, Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis, Cancer Res, 65, 5561, 10.1158/0008-5472.CAN-04-4603 Birchmeier, 2003, Met, metastasis, motility and more, Nat Rev Mol Cell Biol, 4, 915, 10.1038/nrm1261 Lutterbach, 2007, Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival, Cancer Res., 67, 2081, 10.1158/0008-5472.CAN-06-3495 Kaplan, 1985, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Cai, 2004, Semi-parametric estimation of the binomial ROC curve for a continuous diagnostic test, Biostatistics, 5, 573, 10.1093/biostatistics/kxh009 Wolff, 2007, American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol, 25, 118, 10.1200/JCO.2006.09.2775 Wang, 2006, HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors, Cancer Cell, 10, 25, 10.1016/j.ccr.2006.05.023 Cappuzzo, 2006, HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer, N Engl J Med, 354, 2619, 10.1056/NEJMc060020 Sequist, 2008, First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations, J Clin Oncol, 26, 2442, 10.1200/JCO.2007.14.8494 Yang, 2008, Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy, J Clin Oncol, 26, 2745, 10.1200/JCO.2007.15.6695